Cite
HARVARD Citation
Mougalian, S. et al. (n.d.). Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting. Cancer medicine. pp. 4371-4378. [Online].